#USA #New York #Cancer Treatment #Heart Disease #immune checkpoint

New Insights into Cardiovascular Risks from Cancer Therapies

Recent research conducted by a team from NYU Langone Health and its Perlmutter Cancer Center has shown that certain cancer therapies, specifically immune checkpoint inhibitors, may increase the risk of heart disease among patients. These findings have significant implications for the management of cancer patients, especially those with pre-existing cardiovascular conditions.

The Role of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are a powerful class of cancer-fighting drugs that work by blocking specific molecules on immune cells known as immune checkpoints. These molecules function as regulatory mechanisms that prevent the immune system from overreacting. Cancer cells often exploit these checkpoints to evade immune detection, so by inhibiting them, these therapies enhance the body’s ability to target and destroy tumor cells. However, this aggressive immune response may have unintended consequences, particularly for heart health.

Research indicates that while immune checkpoint inhibitors bolster the body's fight against cancer, they may also incite a harmful inflammatory response in various organs, including the heart. This heightened inflammation can contribute to a greater likelihood of cardiovascular events such as heart attacks and strokes. For instance, about 10% of individuals undergoing treatment for atherosclerosis—a condition characterized by the buildup of fatty deposits in arteries—experience cardiovascular incidents post-cancer therapy.

In-Depth Analysis of Immune Response

To understand the correlation between cancer treatments and heart disease risk, the researchers conducted genetic analyses of immune cells taken from plaque tissue of atherosclerosis patients. Their findings suggest a direct link between immune checkpoints targeted by cancer therapies and those present in arterial immune cells. Chiara Giannarelli, MD, PhD, co-senior author of the study, emphasized that this establishes a connection between cancer treatments and increased heart disease risk. It sheds light on the need for vigilance in monitoring cardiovascular health in cancer patients following treatment.

The Impact of Diabetes on Cardiovascular Risks

The study further investigated how factors like Type 2 diabetes, which pose additional risks for both cancer and heart disease, may compound the effects of immune checkpoint inhibitors. The team analyzed immune checkpoint activity in arterial tissue from diabetic patients compared to healthy volunteers. Interestingly, diabetic patients exhibited reduced communication between immune checkpoints, which is believed to exacerbate inflammation. This revelation underscores the complex interplay between cancer therapies, heart disease, and diabetes, indicating that treatment strategies should be tailored accordingly.

Potential for New Intervention Strategies

The investigators also explored how traditional dietary recommendations—such as low-fat diets intended to combat plaque buildup—might be affected by cancer treatments. It was observed in rodent models that a low-fat diet enhances communication between immune checkpoints, suggesting potential anti-inflammatory benefits. However, this natural response may be suppressed in cancer patients receiving immune checkpoint inhibitors, which could interfere with dietary efforts to reduce inflammation.

According to Kathryn Moore, PhD, another co-senior author, the findings emphasize the interconnectedness of cancer, diabetes, and cardiovascular health. With a clearer understanding of how these conditions influence one another, medical professionals can devise more effective strategies for managing patient risks associated with cancer treatments.

The study’s results were published online in the journal Nature Cardiovascular Research on November 29, 2024, leading researchers to advocate for increased awareness among healthcare providers and patients about the potential cardiovascular side effects of cancer therapies.

Conclusion

As the field of oncology evolves, it becomes crucial for oncologists and primary care physicians to work collaboratively in monitoring and managing the overall health of cancer patients. This study signifies a vital step forward in understanding the multifaceted risks tied to cancer treatments, enabling better patient care and potential interventions to mitigate cardiovascular complications in the future.